Cutting Through the Noise

Kratom occupies a unique and contentious position in the opioid crisis conversation. Depending on who you ask, it's either a dangerous drug that should be banned or a life-saving botanical that's keeping people away from fentanyl. The truth, as usual, lives somewhere in the research — and there's more of it than most people realize.

This article examines what peer-reviewed, published research actually says about kratom's pharmacology, its use patterns among opioid users, and the evidence for and against its role in harm reduction. We're not cherry-picking studies to support a conclusion. We're presenting what exists.

How Kratom Works: The Pharmacology

Kratom (Mitragyna speciosa) contains over 40 alkaloids, but two are primarily responsible for its effects:

  • Mitragynine — the most abundant alkaloid, a partial agonist at mu-opioid receptors
  • 7-Hydroxymitragynine (7-OH) — present in smaller quantities but significantly more potent, also a partial agonist at mu-opioid receptors

The term "partial agonist" is important. Unlike full agonists like morphine, fentanyl, or heroin, partial agonists have a ceiling effect — beyond a certain dose, increasing the amount does not proportionally increase the effect. This is the same pharmacological principle behind buprenorphine (Suboxone), an FDA-approved medication for opioid use disorder.

Research published in the Journal of the American Chemical Society (2016) characterized mitragynine as a "biased agonist" at mu-opioid receptors — meaning it activates pain-relief pathways while producing less respiratory depression than classical opioids. This distinction is pharmacologically significant because respiratory depression is the mechanism by which opioid overdoses kill.

What User Surveys Tell Us

Several large-scale surveys have examined why people use kratom and what outcomes they report:

Grundmann (2017), Drug and Alcohol Dependence: Survey of 8,049 kratom users found that 68% used kratom for pain, 66% for emotional/mental conditions, and 41% specifically to reduce opioid use. Among past opioid users, 35% reported no opioid use in the past year.

Smith et al. (2021), Journal of Psychoactive Drugs: Analysis of 2,798 kratom users found that those using kratom to manage opioid withdrawal reported significant reductions in opioid use, withdrawal severity, and cravings.

Garcia-Romeu et al. (2020), Drug and Alcohol Dependence: Survey of 2,474 kratom users found that 89% reported using kratom for pain, and among those with a history of opioid use, the majority reported decreased opioid use and improved quality of life.

These are self-reported surveys with inherent limitations — selection bias, recall bias, and the absence of clinical controls. But the consistency of findings across multiple independent studies, conducted by different research groups, using different methodologies, is noteworthy.

What Clinical Research Shows

Clinical research on kratom in humans is limited, partly because kratom's legal ambiguity makes funding and regulatory approval for clinical trials difficult. However, several important findings have emerged:

Respiratory depression: Animal studies consistently show that mitragynine produces significantly less respiratory depression than morphine at equianalgesic doses. A 2021 study in British Journal of Pharmacology confirmed this in mouse models and proposed the biased agonism mechanism as the explanation.

Overdose potential: While kratom-associated deaths have been reported, the vast majority involve polydrug use — kratom in combination with other substances. The National Institute on Drug Abuse acknowledges that deaths attributed solely to kratom are rare and difficult to confirm.

Withdrawal severity: Research comparing kratom withdrawal to opioid withdrawal consistently finds kratom withdrawal to be milder and shorter in duration. A 2019 systematic review in Journal of Ethnopharmacology found that kratom withdrawal symptoms typically resolve within 3-7 days, compared to weeks for traditional opioids.

The Honest Risks

Responsible analysis requires acknowledging what the research also shows about risks:

  • Dependence — Regular kratom use can produce physical dependence and withdrawal symptoms
  • Contamination — Unregulated kratom products have been found containing heavy metals, salmonella, and adulterants
  • Drug interactions — Kratom alkaloids are metabolized by cytochrome P450 enzymes and can interact with other medications
  • Variability — Unregulated products can have wildly inconsistent alkaloid concentrations between batches
  • Limited long-term data — Most studies are cross-sectional; long-term prospective studies are lacking

These risks are real and should inform both personal decisions and public policy. But they are also manageable through regulation — testing, labeling, concentration limits, and age restrictions address most of these concerns without requiring prohibition.

The Research Gap

The most frustrating aspect of the kratom research landscape is how much we don't know because research has been underfunded and discouraged. The NIH has funded relatively few kratom studies compared to other substances of public health interest. The FDA's adversarial stance has created a chilling effect on academic research.

What we need — and what responsible policy demands — is more research, not less access. Banning a substance that millions of Americans use doesn't generate data. It generates a black market.

At Favor'd Alkz, we support research-informed policy. Every product we sell is independently tested and comes with published alkaloid data that researchers can reference. We believe that transparency at the vendor level contributes to the broader evidence base that the kratom community needs.

Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Kratom products sold by Favor'd Alkz are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.

Last updated: April 2026